Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial - Hu, Chaoying; Tompson, Debra; Magee, Mindy; Chen, Qian; Liu, Yan Mei; Zhu, Wenjing; Zhao, Hongxin; Gross, Annette S.; Liu, Yun (PloS one, 2015)
Keywords: 1-Alkyl-2-acetylglycerophosphocholine Esterase - antagonists & inhibitors; 1-Alkyl-2-acetylglycerophosphocholine Esterase - metabolism; Adult; Approximation; Asian Continental Ancestry Group; Atherosclerosis; Benzaldehydes - administration & dosage; Benzaldehydes - adverse effects; Benzaldehydes - pharmacokinetics; Cardiovascular disease; China; Citrus paradisi; Clinical trials; Cultural differences; Diabetes; Diarrhea; Dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Edema; Enzyme inhibitors; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - pharmacokinetics; Enzymes; Exposure; Family medical history; Female; Healthy Volunteers; Hospitals; Humans; Life assessment; Lipoproteins; Male; Metabolism; Metabolites; Oximes - administration & dosage; Oximes - adverse effects; Oximes - pharmacokinetics; Pharmacodynamics; Pharmacokinetics; Pharmacology; Phospholipase; Phospholipase A2; Prescription drugs; R&D; Research & development; Rhinopharyngitis; Safety; Steady state; Urine; China; United States--US